Develops biologic drugs for cancer treatment, focusing on targeted therapies and antibody-drug conjugates.
Sonnet BioTherapeutics Holdings, Inc. is a biotechnology company in the clinical stage, specializing in oncology treatments. It focuses on developing biologic medicines with single or bispecific actions. One of its innovative technologies is the fully human albumin binding technology, utilizing human single chain antibody fragments that attach to human serum albumin for targeted delivery to tissues. The company's primary product candidate, SON-1010, is a fully human version of interleukin 12 aimed at treating non-small cell lung cancer and head and neck cancer, currently in Phase 1 clinical trials.
In addition to SON-1010, Sonnet BioTherapeutics is advancing SON-080, a fully human interleukin 6 designed for treating chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy, undergoing Phase Ib/IIa studies. Another promising compound in its pipeline is SON-1210, a bispecific molecule developed for solid tumor indications, including colorectal cancer. Sonnet BioTherapeutics holds a license agreement with New Life Therapeutics Pte, LTD. for the development and commercialization of pharmaceutical preparations containing recombinant human interleukin-6.
Headquartered in Princeton, New Jersey, Sonnet BioTherapeutics is dedicated to advancing innovative therapies that address critical unmet needs in oncology. Through strategic partnerships and its proprietary technologies, the company aims to enhance the effectiveness and precision of cancer treatments, promising new hope for patients worldwide.